NervGen Pharma Corp. NGEN
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 724.23% | 93.67% | -539.66% | 53.90% | -137.93% |
| Total Depreciation and Amortization | -0.98% | 2.00% | -0.99% | 0.00% | 4.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -226.75% | -123.07% | 2,430.57% | -119.22% | 980.39% |
| Change in Net Operating Assets | 56.08% | -871.42% | 36.31% | -137.84% | 131.53% |
| Cash from Operations | 30.71% | -30.26% | -18.85% | -45.76% | 7.69% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -66.30% | -1.09% | 0.55% | 3.41% |
| Cash from Investing | -100.00% | -66.30% | -1.09% | 0.55% | 3.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 66.67% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 2,857.29% | -83.28% | 1,441.73% | -77.63% | 179.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -11,383.37% | 75.65% | -157.32% | 44.26% | 68.58% |
| Cash from Financing | 2,686.31% | -83.13% | 1,561.92% | -78.96% | 286.81% |
| Foreign Exchange rate Adjustments | -2,084.63% | -129.97% | 2,662.77% | -114.35% | 311.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,363.11% | -152.31% | 345.37% | -459.86% | 144.64% |